Stop by to review the latest applications of synergistic PET-SPECT-Optical-CT imaging, advanced radionuclide therapy imaging and the preclinical availability of ultra-fast and ultra-high resolution large-bore G-SPECT imaging.
Learn about MILabs’ latest developments in large and small-animal preclinical imaging systems
Scientist in the spotlight: Dr. Sandra Heskamp, Radboud Institute for Molecular Life Sciences
Dr. Sandra Heskamp is an acclaimed researcher at the Radboud Institute for Molecular Life Sciences. As associate professor, she performs pioneering research in the Radiology & Nuclear Medicine department with a focus on immunotherapy and treatment, and rare cancer research.
Over thirty-five scientists at the institute employ MILabs’ SPECT and CT imaging in their research. Using microSPECT/CT, Dr. Heskamp published the first preclinical study ever showing the feasibility of noninvasive in vivo imaging of PD-L1 expression in tumors. This landmark imaging study on immune checkpoint inhibition, is one of the most-referenced articles in the field of anti-PD-1:PD-L1, a research area that according to ResearchGate 2018 is clearly dominating what immunotherapy researchers are reading today.
MILabs products are used in more than 65 countries and are supported by a global network of distributors and factory trained support engineers.
Please contact MILabs directly for more information about your local MILabs business partner.